title: Prostaglandin E(2)-induced interleukin-6 release by a human airway epithelial cell line.
abstract: Human airway epithelial cell release of interleukin (IL)-6 in response to lipid mediators was studied in an airway cell line (BEAS-2B). Prostaglandin (PG) E(2) (10(-7) M) treatment caused an increase in IL-6 release at 2, 4, 8, and 24 h. IL-6 release into the culture medium at 24 h was 3,396 +/- 306 vs. 1,051 +/- 154 pg/ml (PGE(2)-treated cells vs. control cells). PGE(2) (10(-7) to 10(-10) M) induced a dose-related increase in IL-6 release at 24 h. PGF(2 alpha) (10(-6) M) treatment caused a similar effect to that of PGE(2) (10(-7) M). PGE(2) analogs with relative selectivity for PGE(2) receptor subtypes were studied. Sulprostone, a selective agonist for the EP-3 receptor subtype had no effect on IL-6 release. 11-Deoxy-16,16-dimethyl-PGE(2), an EP-2/4 agonist, and 17-phenyl trinor PGE(2), an agonist selective for the EP-1 > EP-3 receptor subtype (10(-6) to 10(-8) M), caused dose-dependent increases in IL-6 release. 8-Bromo-cAMP treatment resulted in dose-related increases in IL-6 release. RT-PCR of BEAS-2B cell mRNA demonstrated mRNA for EP-1, EP-2, and EP-4 receptors. After PGE(2) treatment, increases in IL-6 mRNA were noted at 4 and 18 h. Therefore, PGE(2) increases airway epithelial cell IL-6 production and release.
authors.affiliation: Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: S
authors.initials: S
authors.lastname: Tavakoli
authors.forename: M J
authors.initials: MJ
authors.lastname: Cowan
authors.forename: T
authors.initials: T
authors.lastname: Benfield
authors.forename: C
authors.initials: C
authors.lastname: Logun
authors.forename: J H
authors.initials: JH
authors.lastname: Shelhamer
mesh_terms: D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D001980:Bronchi / Q000166:cytology; D002461:Cell Line, Transformed; D002630:Chemotactic Factors / Q000494:pharmacology; D015232:Dinoprostone / Q000235:genetics / Q000494:pharmacology*; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D015870:Gene Expression / Q000276:immunology; D006367:HeLa Cells; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000494:pharmacology; D015850:Interleukin-6 / Q000378:metabolism*; D007975:Leukotriene B4 / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000494:pharmacology; D011014:Pneumonia / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D020545:Respiratory Mucosa / Q000166:cytology / Q000276:immunology* / Q000378:metabolism*
chemical_list: D002630:Chemotactic Factors; D006893:Hydroxyeicosatetraenoic Acids; D015850:Interleukin-6; D010972:Platelet Activating Factor; D012333:RNA, Messenger; D007975:Leukotriene B4; D015124:8-Bromo Cyclic Adenosine Monophosphate; C022022:5-hydroxy-6,8,11,14-eicosatetraenoic acid; D015232:Dinoprostone